Atp Life Science Ventures, L.p. - Net Worth and Insider Trading
Atp Life Science Ventures, L.p. Net Worth
The estimated net worth of Atp Life Science Ventures, L.p. is at least $423 Million dollars as of 2024-11-13. Atp Life Science Ventures, L.p. is the 10% Owner of Stoke Therapeutics Inc and owns about 17,161,713 shares of Stoke Therapeutics Inc (STOK) stock worth over $234 Million. Atp Life Science Ventures, L.p. is also the 10% Owner of Akero Therapeutics Inc and owns about 5,830,203 shares of Akero Therapeutics Inc (AKRO) stock worth over $189 Million. Details can be seen in Atp Life Science Ventures, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Atp Life Science Ventures, L.p. has not made any transactions after 2020-11-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Atp Life Science Ventures, L.p.
Atp Life Science Ventures, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Atp Life Science Ventures, L.p. owns 5 companies in total, including Akero Therapeutics Inc (AKRO) , Stoke Therapeutics Inc (STOK) , and Avalo Therapeutics Inc (AVTX) among others .
Click here to see the complete history of Atp Life Science Ventures, L.p.’s form 4 insider trades.
Insider Ownership Summary of Atp Life Science Ventures, L.p.
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
AKRO | Akero Therapeutics Inc | 2021-06-28 | 10 percent owner |
STOK | Stoke Therapeutics Inc | 2021-06-28 | 10 percent owner |
AVTX | Avalo Therapeutics Inc | 2015-10-14 | director & 10 percent owner |
2014-09-22 | director & 10 percent owner | ||
2013-11-25 | 10 percent owner |
Atp Life Science Ventures, L.p. Latest Holdings Summary
Atp Life Science Ventures, L.p. currently owns a total of 2 stocks. Among these stocks, Atp Life Science Ventures, L.p. owns 17,161,713 shares of Stoke Therapeutics Inc (STOK) as of November 24, 2020, with a value of $234 Million and a weighting of 55.32%. Atp Life Science Ventures, L.p. also owns 5,830,203 shares of Akero Therapeutics Inc (AKRO) as of July 10, 2020, with a value of $189 Million and a weighting of 44.68%.
Latest Holdings of Atp Life Science Ventures, L.p.
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
STOK | Stoke Therapeutics Inc | 2020-11-24 | 17,161,713 | 13.62 | 233,742,531 |
AKRO | Akero Therapeutics Inc | 2020-07-10 | 5,830,203 | 32.38 | 188,781,973 |
Holding Weightings of Atp Life Science Ventures, L.p.
Atp Life Science Ventures, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Atp Life Science Ventures, L.p. has made a total of 1 transactions in Stoke Therapeutics Inc (STOK) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Stoke Therapeutics Inc is the acquisition of 375,000 shares on November 24, 2020, which cost Atp Life Science Ventures, L.p. around $15 Million.
According to the SEC Form 4 filings, Atp Life Science Ventures, L.p. has made a total of 1 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akero Therapeutics Inc is the acquisition of 415,000 shares on July 10, 2020, which cost Atp Life Science Ventures, L.p. around $15 Million.
Insider Trading History of Atp Life Science Ventures, L.p.
- 1
Atp Life Science Ventures, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Atp Life Science Ventures, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Atp Life Science Ventures, L.p. is -1.56%. GuruFocus also compares Atp Life Science Ventures, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Atp Life Science Ventures, L.p. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Atp Life Science Ventures, L.p.'s insider trading performs compared to the benchmark.
Performance of Atp Life Science Ventures, L.p.
Atp Life Science Ventures, L.p. Ownership Network
Ownership Network List of Atp Life Science Ventures, L.p.
Ownership Network Relation of Atp Life Science Ventures, L.p.
Atp Life Science Ventures, L.p. Owned Company Details
What does Akero Therapeutics Inc do?
Who are the key executives at Akero Therapeutics Inc?
Atp Life Science Ventures, L.p. is the 10 percent owner of Akero Therapeutics Inc. Other key executives at Akero Therapeutics Inc include Chief Development Officer Catriona Yale , director & President & CEO Andrew Cheng , and Chief Operating Officer Jonathan Young .
Akero Therapeutics Inc (AKRO) Insider Trades Summary
Over the past 18 months, Atp Life Science Ventures, L.p. made no insider transaction in Akero Therapeutics Inc (AKRO). Other recent insider transactions involving Akero Therapeutics Inc (AKRO) include a net sale of 171,998 shares made by Jonathan Young , a net sale of 150,584 shares made by Catriona Yale , and a net sale of 443,502 shares made by Andrew Cheng .
In summary, during the past 3 months, insiders sold 488,023 shares of Akero Therapeutics Inc (AKRO) in total and bought 0 shares, with a net sale of 488,023 shares. During the past 18 months, 1,237,763 shares of Akero Therapeutics Inc (AKRO) were sold and 1,320,000 shares were bought by its insiders, resulting in a net purchase of 82,237 shares.
Akero Therapeutics Inc (AKRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Akero Therapeutics Inc Insider Transactions
Atp Life Science Ventures, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Atp Life Science Ventures, L.p.. You might contact Atp Life Science Ventures, L.p. via mailing address: 230 Park Avenue, Suite 2800, New York Ny 10169.